---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-208814"
form_type: "8-K"
ticker: null
cik: "0001808158"
company_name: "Repare Therapeutics Inc."
filed_at: "2024-08-28T23:59:59+00:00"
generated_at: "2026-05-31T07:13:37.776198+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Repare Therapeutics cuts workforce 25%, focuses on four clinical programs, extends cash runway to H2 2026

## Summary
- Board approved reprioritization; workforce reduction of ~25%, mainly in preclinical group, affected employees notified Aug 28, 2024.
- Expected one-time cash charges of $1.5M-$2.0M for termination benefits; substantially complete by Q3 2024.
- Annual cost savings of ~$15M extend cash runway into second half of 2026.
- Upcoming milestones: lunresertib+camonsertib data Q4 2024; potential registrational trial 2025; RP-3467 Phase 1 start Q4 2024.
- RP-1664 Phase 1 LIONS trial ongoing; plans to advance into pediatric neuroblastoma Phase 1/2 after safety data.

## SEC filing metadata
- accession: 0001193125-24-208814
- form_type: 8-K
- cik: 0001808158
- company_name: Repare Therapeutics Inc.
- filed_at: 2024-08-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808158/000119312524208814/0001193125-24-208814-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808158/000119312524208814/d833928d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-208814
- JSON: https://secwatch.observer/filing/0001193125-24-208814.json
- Plain text: https://secwatch.observer/filing/0001193125-24-208814.txt

## Key facts
- Restructurings & Charges
  Repare Therapeutics Inc. announced a restructuring with charges of termination benefits affecting workforce reduction (approximately 25%).
  - Type: restructuring
  - Charge: termination benefits
  - Affected area: workforce reduction
  - Headcount: approximately 25%
  source text: the Company plans to reduce its overall workforce by approximately 25%, with the majority of the headcount reductions from the Company’s preclinical group, with affected employees notified on August 28, 2024. The Company expects to recognize total charges in connection with the Plan in the range of approximately $1.5 million to $2.0 million, consisting of one-time cash charges for termination benefits.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808158/000119312524208814/0001193125-24-208814-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.